Medline Inc. Q3 2026 Earnings Recap

Medline’s shares rose 18.4% after earnings, with investors responding to 10% sales growth and 12% growth in adjusted EBITDA. The quarter also showed margin pressures from inflation, customer mix, and higher operating expenses, while management flagged near-term pressure and ongoing quality investments.

Key Takeaways

• Third-quarter net sales increased 10% year over year to $7.9 billion, driven almost entirely by organic growth.
• Adjusted EBITDA rose 12% to $1 billion; management cited strong sales and tariff refunds as tailwinds, partly offset by higher operating expenses, inflation-related costs, and customer mix.
• Supply Chain Solutions sales grew 14% to $4.2 billion, while Medline Brand sales increased 7% to $3.6 billion.
• U.S. acute care sales grew 12% to $5.5 billion; nonacute care rose 6% to $1.9 billion. International sales increased 8% to $518 million.
• Management said near-term margin pressure remains a focus. Global quality assessments across more than 30 manufacturing sites are expected to take multiple years; related investments are reflected in 2026 guidance and the 2027 framework.